**Supplemental Materials**

C

C

A

C

C

C

**Supplemental Table 1.** Details for the studies included in this meta-analysis

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | Diagnostic  Assay | In/Out  patient | Wk1  OP[[1]](#footnote-1) | Wk2  OP | Wk3  OP | Total | Wk1  NP | Wk2  NP | Wk3  NP | Total | Wk1  SP | Wk2  SP | Wk3  SP | Total |
| Kujawski et al (2020)10 | RT-PCR | In & Out | 13/18 | 15/38 | 9/63 | 37/120 | 13/19 | 21/38 | 11/64 | 48/121 | 5/5 | 7/9 | 3/6 | 15/20 |
| Kim et al (2020)6 | RT-PCR (E) | In | .. | .. | .. | .. | 30/31 | 19/30 | 2/11 | 51/72 | 25/26 | 15/26 | 1/9 | 41/61 |
| Lin et al (2020)11 | RT-PCR (ORF1ab, N) | In | .. | .. | .. | 23/44 | .. | .. | .. | .. | .. | .. | .. | 40/44 |
| Yu et al (2020)5 | RT-PCR (ORF1ab, N) | In | .. | .. | .. | 62/96 | .. | .. | .. | 14/55 | .. | .. | .. | 86/116 |
| Wang et al (2020)2 | RT-PCR (ORF1ab) | In | .. | .. | .. | 126/398 | .. | .. | .. | 5/8 | .. | .. | .. | 72/104 |
| Yang et al (2020)12 | RT-PCR | In & Out | 58/95 | 26/63 | 15/47 | 99/205 | 158/219 | 130/226 | 23/45 | 311/490 | 45/54 | 47/61 | 14/25 | 106/140 |
| Chan et al (2020)1 | RT-PCR (S) | .. | .. | .. | .. | 2/5 | .. | .. | .. | 4/5 | .. | .. | .. | 2/5 |
| Chen et al (2020)13 | RT-PCR(E) | In | 37/44 | 17/57 | 11/93 | 65/194 | .. | .. | .. | .. | 15/15 | 28/38 | 124/194 | 167/247 |
| Lo et al (2020)14 | RT-PCR (ORF1ab, N) | In | .. | .. | .. | .. | 28/36 | 17/24 | 9/16 | 57/84 | 1/1 | 0/0 | 0/0 | 1/1 |
| Wu et al (2020)7 | RT-PCR | In | .. | .. | .. | .. | .. | .. | .. | 180/472 | .. | .. | .. | 148/304 |
| Pan et al (2020)15 | RT-PCR (N) | In | 8/9 | 2/12 | 0/1 | 10/22 | .. | .. | .. | .. | 6/7 | 4/10 | 0/1 | 10/18 |

**Supplemental Table 2.** Participant inclusion criteria for each study.

|  |  |  |
| --- | --- | --- |
|  | SARS-CoV-2 inclusion criteria for included participants | |
| Kujawski et al (2020)10 | | Positive RT-PCR in NP swab or OP swab or sputum |
| Kim et al (2020)6 | | Positive RT-PCR in NP swab or OP swab |
| Lin et al (2020)11 | | Positive RT-PCR in both OP swab and sputum specimen |
| Yu et al (2020)5 | | Positive RT-PCR in NP swab or OP swab or sputum |
| Wang et al (2020)2 | | Positive RT-PCR from an unspecified site |
| Yang et al (2020)12 | | Confirmed per “Chinese CDC guideline" |
| Chan et al (2020)1 | | Positive RT-PCR from NP swab or OP swab or serum |
| Chen et al (2020)13 | | At least two RT-PCR positive OP swabs |
| Lo et al (2020)14 | | Positive RT-PCR in NP swab or sputum |
| Wu et al (2020)7 | | Positive RT-PCR in NP swab |
| Pan et al (2020)15 | | Positive RT-PCR in OP swab or sputum |

NP, nasopharyngeal; OP, oropharyngeal

1. Week 1 (Wk1), week 2 (Wk2) and week 3(Wk3) are 0-7, 8-14 and >14 days after symptoms onset, retrospectively. Virus detection in oropharyngeal (OP), nasopharyngeal (NP) and sputum (SP) samples. [↑](#footnote-ref-1)